Odds of moderate or severe gastric ulceration in racehorses receiving antiulcer medications.
Abstract: To determine the odds of moderate or severe gastric ulceration in racehorses treated with various antiulcer medications. Methods: Unmatched case-control study. Methods: 798 horses in active race training (252 Thoroughbreds and 546 Standardbreds). Only horses that had been receiving a single antiulcer medication or no antiulcer medication for at least 2 weeks prior to examination were included. Methods: Gastroscopy was performed on each horse by a single individual who was not aware of the horses' antiulcer treatments, and severity of gastric ulceration was scored. Signalment and medication history were recorded. Logistic regression was used to determine whether identification of moderate or severe ulceration was associated with treatment, age, breed, or sex. Treatments were grouped as no treatment, buffer, sucralfate, histamine type 2 receptor antagonist, compounded omeprazole, proprietary omeprazole at a low dosage, and proprietary omeprazole at a high dosage. Results: Only proprietary omeprazole was associated with significantly lower odds of moderate or severe ulceration, compared with no treatment. Risks of moderate or severe gastric ulceration in horses receiving a buffer, sucralfate, a histamine type 2 receptor antagonist, or compounded omeprazole were not significantly different from risks in horses receiving no antiulcer medication. Conclusions: Results suggest that the proprietary formulation of omeprazole was associated with a significantly lower risk of moderate or severe gastric ulceration, compared with no treatment, in racehorses in active race training, whereas other antiulcer medications were not.
Publication Date: 2003-08-09 PubMed ID: 12906229DOI: 10.2460/javma.2003.223.336Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research study investigates the effectiveness of various antiulcer medications in reducing moderate or severe gastric ulcers in racehorses. It finds that only the proprietary omeprazole is linked with a significantly lower risk of these conditions compared with no treatment, while the other antiulcer medications tested do not show significant impact.
Research Methods
- An unmatched case-control study was conducted on 798 racehorses currently in training, broken down into 252 Thoroughbreds and 546 Standardbreds.
- To qualify for the study, a horse must have been administered a single antiulcer medication or none at all for a minimum period of 2 weeks before the examination.
- Each of the horses was gastroscoped by an unaware examiner, who then gauged the severity of any gastric ulceration found.
- The steeds’ signalment (which pertains to their distinguishing traits such as breed, sex, and age) and their medication history were recorded.
- Statistical analysis, using logistic regression, was employed to assess any relationship between the presence of moderate or severe ulceration, and specific variables like treatment, age, breed, and sex.
Research Findings
- Treatment types were classified into seven groups: no treatment, buffer, sucralfate, histamine type 2 receptor antagonist, compounded omeprazole, and proprietary omeprazole (low dose and high dose).
- It was found that the only notable lower odds of moderate or severe ulceration were associated with proprietary omeprazole, when compared to no treatment.
- Horses receiving a buffer, sucralfate, a histamine type 2 receptor antagonist, or compounded omeprazole had risk levels for moderate or severe gastric ulceration that were not significantly different from risks in horses receiving no treatment.
Conclusion
- The findings suggest that proprietary omeprazole offers a significant reduction in risk of moderate or severe gastric ulceration in racehorses actively in race training.
- Other antiulcer treatments, however, didn’t show significant impact on reducing these conditions when compared with no treatment.
Cite This Article
APA
Orsini JA, Haddock M, Stine L, Sullivan EK, Rabuffo TS, Smith G.
(2003).
Odds of moderate or severe gastric ulceration in racehorses receiving antiulcer medications.
J Am Vet Med Assoc, 223(3), 336-339.
https://doi.org/10.2460/javma.2003.223.336 Publication
Researcher Affiliations
- New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA.
MeSH Terms
- Age Factors
- Animals
- Anti-Ulcer Agents / therapeutic use
- Breeding
- Case-Control Studies
- Female
- Gastroscopy / veterinary
- Horse Diseases / drug therapy
- Horse Diseases / epidemiology
- Horse Diseases / prevention & control
- Horses
- Male
- Omeprazole / therapeutic use
- Risk Factors
- Severity of Illness Index
- Sports
- Stomach Ulcer / drug therapy
- Stomach Ulcer / epidemiology
- Stomach Ulcer / prevention & control
- Stomach Ulcer / veterinary
- Treatment Outcome
Citations
This article has been cited 2 times.- Hwang H, Dong HJ, Han J, Cho S, Kim Y, Lee I. Prevalence and treatment of gastric ulcers in Thoroughbred racehorses of Korea. J Vet Sci 2022 Mar;23(2):e19.
- Shephard RJ. Peptic Ulcer and Exercise. Sports Med 2017 Jan;47(1):33-40.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
